

2023 Raleigh Campus Antibiogram Inpatient

GRAM POSITIVE								
Antibiogram 2023 Raleigh Campus Inpatient	*Anaerobic coverage	Enterococcus faecalis	Enterococcus faecium	Staphylococcus epidermidis	Staphylococcus hominis	Staph aureus (MSSA)	Staph aureus (MRSA)	Staphylococcus lugdunensis
Location		INPATIENTS						
# of isolates analyzed		462	57	206	31	591	480	32
		% Susceptible						
Ampicillin	*	100%	26%					
Ceftaroline						100%	100%	
Clindamycin	*			61%	72%	78%	76%	78%
Daptomycin						100%	99%	
Erythromycin Base, Enteric	*			33%	48%	64%	14%	78%
Gentamicin Synergy (high level)		85%	96%					
Levofloxacin		82%	28%					
Linezolid		98%	93%	99%	100%	100%	100%	100%
Nitrofurantoin		99%	23%	100%	97%	100%	100%	100%
Oxacillin				40%	45%	100%	0%	72%
Penicillin G	*	98%	25%	0%	0%	0%	0%	0%
Streptomycin Synergy (high level)		92%	67%					
Tetracycline/Doxycycline	*			78%	81%	96%	84%	100%
Trimethoprim-sulfa				63%	73%	97%	83%	100%
Vancomycin		98%	49%	100%	100%	100%	100%	100%

This antibiogram has been prepared from SCC SOFT LIS.
 This antibiogram contains organisms isolated in 2022.
 Only the first isolate per patient is included in this data.
 * Denotes activity against anaerobes. Anaerobes are not tested for
 susceptibility profiles at WakeMed.

19 % of Inpatient MSSA are Clindmycin Inducible Resistant
 4% of Inpatient MRSA are Clindamycin Inducible Resistant

**Antibiograms are published annually for WakeMed Raleigh, WakeMed Cary and WakeMed North
 by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075**

**WakeMed Health and Hospitals
 Raleigh, NC**